2-(3-氯苯基)喹啉-4-羧酸 | 20389-10-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-(3-氯苯基)喹啉-4-羧酸
• 中文别名: 2-(3-氯苯基)-4-喹啉羧酸
• 英文名称: 2-(3-chlorophenyl)quinoline-4-carboxylic acid
• 英文别名: 2-(3-chloro-phenyl)-quinoline-4-carboxylic acid；2-(3-Chlor-phenyl)-chinolin-4-carbonsaeure；2-(3-Chlorphenyl)-chinolin-4-carbonsaeure
• CAS: 20389-10-0
• 化学式: C₁₆H₁₀ClNO₂
• mdl: MFCD02055964
• 分子量: 283.714
• InChiKey: QPDXYIKQOBZSGQ-UHFFFAOYSA-N

物化性质

• 熔点：
  214
• 沸点：
  483.3±40.0 °C(Predicted)
• 密度：
  1.373±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2933499090
• 储存条件：
  储存温度应保持在2-8°C，需密封并确保干燥。

反应信息

• 作为反应物：
  描述：

  2-(3-氯苯基)喹啉-4-羧酸 在 草酰氯 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 2-(3-chlorophenyl)quinoline-4-carbonyl Chloride
  参考文献：
  名称：

  发现了一类新型的针对人类神经激肽3受体的选择性非肽拮抗剂。1.鉴定4-喹啉羧酰胺框架。

  摘要：

  基于化学上不同的NK-1受体拮抗剂，设计了一种新型的有效且选择性的非肽神经激肽3（NK-3）受体拮抗剂，其特征在于4-喹啉羧酰胺骨架。通过原型4的化学修饰促进了新型化合物33-76的表达，其特征在于使用表达人神经激肽3受体（hNK-3-CHO）的中国仓鼠卵巢（CHO）细胞膜制剂进行结合分析，并建立了明确的结构-活性关系（SAR）。从SARs（R）-N- [α-（甲氧基羰基）苄基] -2-苯基喹啉-4-羧酰胺（65，SB 218795，hNK-3-CHO结合Ki = 13 nM）出现，是最有效的化合物之一这个新颖的班级。对其他神经激肽受体（hNK-2-CHO和hNK-1-CHO）的选择性研究表明，对hNK-3的选择性是对hNK-2受体的65倍（hNK-2-CHO结合Ki = 1221 nM）。相对于hNK-1受体具有超过7000倍的选择性（hNK-1-CHO结合Ki => 100 micro

  DOI：

  10.1021/jm960818o
• 作为产物：
  描述：

  2-羟基亚氨基-n-苯乙酰胺 在 硫酸 、 potassium hydroxide 作用下， 以 乙醇 、 水 为溶剂， 生成 2-(3-氯苯基)喹啉-4-羧酸
  参考文献：
  名称：

  Design, synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety

  摘要：

  A series of novel bisquinoline derivatives connected by a 4-oxy-3-fluoroaniline moiety were synthesized and evaluated for their in vitro antitumour activities against a panel of five cancer cell lines (H460, HT-29, MKN-45, U87MG, and SMMC-7721). Most of compounds tested showed a potent activity and high selectivity towards the H460 and MKN-45 cell lines. Among the compounds tested, six (15d, 15e, 15m, 15n, 16a, and 16i) were further examined for their c-Met kinase activity; the compounds showed high efficacy with IC50 values in the single-digit nM range. An analysis of structure activity relationships indicated that an unsubstituted or a halogen-substituted phenyl ring on the 2-arylquinoline-4-carboxamide moiety was favourable for antitumour activity. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.04.001

文献信息

• Exploration of 2-phenylquinoline-4-carboxamide linked benzene sulfonamide derivatives as isoform selective inhibitors of transmembrane human carbonic anhydrases
  作者：Baijayantimala Swain、Santosh Kumar Sahoo、Priti Singh、Andrea Angeli、Venkata Madhavi Yaddanapudi、Claudiu T. Supuran、Mohammed Arifuddin

  DOI：10.1016/j.ejmech.2022.114247

  日期：2022.4

  A novel series of 32 sulfonamide containing quinolines (5a-j, 7a-k and 9a-k) were synthesized using tail approach and assayed for their carbonic anhydrase inhibitory potency against four human (h) carbonic anhydrase (CA) isoforms hCA I, II, IX and XII. Most of these newly synthesized compounds exhibited interesting inhibition potency against hCA I, II, IX and XII, in the nanomolar range with some derivatives

  使用尾部方法合成了一系列新的含有 32 种磺酰胺的喹啉（5a-j、7a-k和9a-k） ，并测定了它们对四种人 (h) 碳酸酐酶 (CA) 异构体 hCA I、II 的碳酸酐酶抑制效力，九和十二。大多数这些新合成的化合物在纳摩尔范围内对 hCA I、II、IX 和 XII 表现出有趣的抑制效力，其中一些衍生物比标准药物乙酰唑胺 ( AAZ ) 更有效。在 hCA I 上最有效的是9b (91.8 nM)，在 hCA II 上：5b ( 7.1 nM)、9c (9.6 nM) 和在 hCA IX 上：5b (6.5 nM) 、5g (21.4 nM), 5i (9.1 nM) , 9a (22.8 nM) , 9b (9.7 nM)。发现化合物5h (8.8 nM)、7a (9.6 nM)、9d (6.9 nM)、9e (6.7 nM) 对 hCA XII 非常有效。发现这些 4-官能化苯磺酰胺
• Exploration of Isoxazole‐Carboxylic Acid Methyl Ester Based 2‐Substituted Quinoline Derivatives as Promising Antitubercular Agents
  作者：Santosh Kumar Sahoo、Mohammad Naiyaz Ahmad、Grace Kaul、Srinivas Nanduri、Arunava Dasgupta、Sidharth Chopra、Venkata Madhavi Yaddanapudi

  DOI：10.1002/cbdv.202200324

  日期：2022.7

  pursuit of potent anti-TB agents active against drug resistant tuberculosis (DR-TB), herein we report synthesis and bio-evaluation of a new series of isoxazole-carboxylic acid methyl ester based 2-substituted quinoline derivatives. Preliminary evaluation indicated selectivity towards Mtb H37Rv, with no inhibition of non-tubercular mycobacterial (NTM) & bacterial pathogen panel. Out of 36 synthesized compounds

  为了追求对耐药结核病 (DR-TB) 有活性的有效抗结核药物，我们在此报告了一系列基于异恶唑-羧酸甲酯的 2-取代喹啉衍生物的合成和生物评价。初步评估表明对 Mtb H37Rv 具有选择性，对非结核分枝杆菌 (NTM) 和细菌病原体组没有抑制作用。在 36 种合成化合物中，大多数化合物对 Mtb H37Rv 具有显着抑制作用（MIC 0.5-8 μg/mL）。针对 Vero 细胞的细胞活力测试显示没有显着的细胞毒性。此外，针对耐药菌株 (DR-Mtb) 的筛选发现命中化合物显示出有希望的效力 (MIC 1-4 μg/mL)。命中的结构优化导致了先导化合物的鉴定，证明了对药物敏感的 Mtb (MIC 0. 12 μg/mL) 和耐药 Mtb (MIC 0.25-0.5 μg/mL) 以及高选择性指数 (SI) >80。总之，具有可观的选择性和有效的活性，这些化学型显示出有望成为潜在的抗结核病候选者。
• α-(2-Piperidyl)-2-aryl-4-quinolinemethanols¹
  作者：Ronald F. Brown、Thomas L. Jacobs、S. Winstein、Milton C. Kloetzel、Earl C. Spaeth、Warner H. Florsheim、John H. Robson、Edward F. Levy、George M. Bryan、Alan B. Magnusson、Stanley J. Miller、Melvin L. Ott、Joseph A. Terek

  DOI：10.1021/ja01216a087

  日期：1946.12
• STAT3 INHIBITOR CONTAINING QUINOLINECARBOXAMIDE DERIVATIVE AS ACTIVE INGREDIENT
  申请人：General Incorporated Association Pharma Valley Project Supporting Organization

  公开号：EP2325181B1

  公开（公告）日：2017-03-29
• Discovering novel chemical inhibitors of human cyclophilin A: Virtual screening, synthesis, and bioassay
  作者：Jian Li、Jing Chen、Chunshan Gui、Li Zhang、Yu Qin、Qiang Xu、Jian Zhang、Hong Liu、Xu Shen、Hualiang Jiang

  DOI：10.1016/j.bmc.2005.11.006

  日期：2006.4

  Cyclophilin A (CypA) is a member of cyclophilins, a family of the highly homologous peptidyl prolyl cis-trans isomerases (PPIases), which can bind to cyclosporin A (CsA). CypA plays critical roles in various biological processes, including protein folding, assembly, transportation, regulation of neuron growth, and HIV replication. The discovery of CypA inhibitor is now of a great special interest in the treatment of immunological disorders. In this study, a series of novel small molecular CypA inhibitors have been discovered by using structure-based virtual screening in conjunction with chemical synthesis and bioassay. The SPECS-1 database containing 85,000 small molecular compounds was searched by virtual screening against the crystal structure of human CypA. After SPR-based binding affinity assay, 15 compounds were found to show binding affinities to CypA at submicro-molar or micromolar level (compounds 1-15). Seven compounds were selected as the starting point for the further structure modification in considering binding activity, synthesis difficulty, and structure similarity. We thus synthesized 40 new small molecular compounds (1-6, 15, 16a-q, 17a-d, and 18a-I), and four of which (compounds 16b, 16h 16k,. and 18g) showed high CypA PPIase inhibition activities with IC50S of 2.5-6,2 mu M. Pharmacological assay indicated that these four Compounds demonstrated somewhat inhibition activities against the proliferation of spleen cells. (c) 2005 Elsevier Ltd. All rights reserved.